In new industries like psychedelic medicine, it’s usually the biggest names that get the most attention. With the space still getting its feet under itself, this reliance on the space’s few household names is a normal and perhaps necessary cliche — legitimacy often comes, especially when dealing with the general public, by perceived success.
So while ATAI and MindMed draw more eyeballs and investors to the sector, smaller firms have the chance to do their early work while the wider industry grows around them.
MindBio Therapeutics is one of these newer companies, describing itself as a clinical-stage drug development company pioneering microdosing research and advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD.
For an under-the-radar newcomer, MindBio has built a pretty impressive early pipeline. With a focus on LSD and microdosing, the company is carving itself an interesting niche in the market. Here’s a look at their development programs (info taken from the company website).
Phase 1 Clinical Trial: Microdosing LSD
MindBio’s scientific team is completing a world-first clinical trial of its kind, administering LSD microdoses in 80 healthy patients, with treatments taken at home. The trial is already underway.
Phase 2 Clinical Trial: Microdosing in Late Stage Cancer Patients
Developing a Phase 2 clinical trial in late stage cancer patients. This study will evaluate the feasibility of conducting a randomised controlled trial examining the feasibility of psychedelic-microdose assisted therapy. Participants will be randomised to receive psychotherapy alongside doses of either psilocybin or LSD microdose or placebo.
Phase 2 Clinical Trial: Microdosing LSD for Major Depressive Disorder
The target indication is MDD and the trial is in preparation stages for a Phase 2 clinical trial this year, examining the use of LSD microdosing.
With its focus on developing LSD therapeutics, MindBio was a perfect fit for Microdose’s recent LSD Conference (our virtual conference exploring the potential of LSD). MindBio co-founder Justin Hanka kicked off the conference with a presentation during the “Emerging Treatments in Mental Health” panel. See below for a clip of MindBio’s presentation:
Interested in more about on what this company is working on? See here for more information on MindBio’s research and company profile.